← Back to Clinical Trials
Recruiting Phase 4 NCT05640453

Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting

Trial Parameters

Condition Pregabalin
Sponsor Tanta University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 70
Sex ALL
Min Age 65 Years
Max Age N/A
Start Date 2022-12-15
Completion 2026-05-15
Interventions
PregabalinDexmedetomidine

Brief Summary

The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.

Eligibility Criteria

Inclusion Criteria: * CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD). Exclusion Criteria: * Patients who had history of psychiatric diseases; inability to communicate; * previous history of POD; preoperative sick sinus syndrome, allergy/sensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \<50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency. * Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.

Related Trials